on october 6, 2014, chimerix received an fda authorization for emergency investigational new drug applications of brincidofovir for the treatment of ebola virus disease. brincidofovir was administered to the first patient diagnosed in the ebola virus disease outbreak in the us in 2014. the patient was given the drug starting six days after hospital admission when he was already critically ill; he died four days later. brincidofovir was also given to ebola patient ashoka mukpo at the nebraska medical center, who had developed the disease and then was pronounced ebola-free and released from the center on 22 october 2014.